The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 601–700 of 979
The cyclical revival of psychedelics in psychiatric treatment
Appiani, F. J., & Caroff, S. N. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2368725 · Cited by 5
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00364 · Cited by 5
Hunt, H. T. (2022) · The International Journal of Transpersonal Studies · doi:10.24972/ijts.2021.40.1.1 · Cited by 5
Transpersonal Perspectives on Mental Health and Mental Illness
Kaminker, J., & Lukoff, D. G. (2013) · Wiley eBooks · doi:10.1002/9781118591277.ch23 · Cited by 5
Farré, M., Papaseit, E., Fonseca, F., & Torrens, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_19 · Cited by 5
Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances ☆
Emerson, B., & Haden, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66208-6 · Cited by 5
Jones, R. H. (2022) · Religions · doi:10.3390/rel13070650 · Cited by 5
Sharp, P. E. (2013) · Religion Brain & Behavior · doi:10.1080/2153599x.2013.826717 · Cited by 5
Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances
Emerson, B., & Haden, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00510-5 · Cited by 5
Bouso, J. C., Pérez, E. J. P., Gandy, S., & Alcázar‐Córcoles, M. Á. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2570 · Cited by 5
Big Five personality and the psychedelic experience: An initial report
Kajonius, P., Sjöström, D., & Claesdotter‐Knutsson, E. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00414 · Cited by 4
Psychedelics and the future evolution of humanity
Winkelman, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00464 · Cited by 4
Koning, E., McMillan, R. M., Keshen, A. R., Hay, P., Fernandez, A. V., Reynolds, J., & Touyz, S. W. (2025) · Journal of Eating Disorders · doi:10.1186/s40337-025-01394-9 · Cited by 4
Payne, J., Robinson, O. C., Arnaud, K. O. S., Aday, J. S., Warner, M., Ludlow, C., & Murray, G. (2025) · Brain and Behavior · doi:10.1002/brb3.71043 · Cited by 4
The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors
Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 4
A causal pluralist theory of the interaction of substance, set and setting in psychedelic experience
Kiverstein, J. D., Beyköylü, H., & van Elk, M. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2590741 · Cited by 4
Exploring Mystical-Type Experiences Through Auto-Induced Cognitive Trance
Bicego, A., Alnagger, N., Cardeña, E., Sombrun, C., Martial, C., Annen, J., Gosseries, O., & Vanhaudenhuyse, A. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2544055 · Cited by 4
Beyköylü, H., Vervaeke, J., & Meling, D. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2601717 · Cited by 4
Carlisle, N. A., Simonsson, O., MacCarthy, S., Elliott, M. N., Miller, G. H., Goldberg, S. B., Shallcross, R. A., & Hendricks, P. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-37609-5 · Cited by 4
Simpson, R. J., & Juruena, M. F. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07003-0 · Cited by 4
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 4
Seeing in Visionary and Mystical Experience: A Perceptual and Cognitive-Semantic Account
Stocker, K. (2022) · Cognitive Semantics · doi:10.1163/23526416-bja10030 · Cited by 4
Baker, K. M., Ulrich, C. M., & Meghani, S. H. (2023) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221147700 · Cited by 4
Mechanisms of integration in psychedelic-assisted therapy
Coverdale, N. S., & Cook, D. J. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0014 · Cited by 4
Belief change and agnostic frames in psychedelic research and clinical contexts
Yaden, D. B., Nayak, S. M., & Griffiths, R. R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0008 · Cited by 4
Self-citationLatin American adults who regularly use macrodoses of psychedelics: a cross-sectional study
Véliz‐García, Ó., & Domic‐Siede, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-74590-3 · Cited by 4
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
Hu, X., Gorman, I., & Nielson, E. M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_529 · Cited by 4
Leonard, D., & Brooks, T. R. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251330066 · Cited by 4
Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences
Macallan, B. C. (2023) · Religions · doi:10.3390/rel14101312 · Cited by 4
A Psychometric Evaluation of the Dutch Revised Mystical Experience Questionnaire
Wirsching, A., Bostoen, T., & Huizink, A. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2272832 · Cited by 4
Exploring serotonergic psychedelics as a treatment for personality disorders
Carrithers, B. M., Roberts, D. E., Weiss, B., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., & Zeifman, R. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110413 · Cited by 4
Beesley, V. L., Kennedy, T., Maccallum, F., Ross, M., Harvey, R., Rossell, S. L., Sarris, J. J., Perkins, D., Neale, R. Ε., Bennett–Levy, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095992 · Cited by 4
The psychedelic-peptide paradox: a hormetic hypothesis
Carter, C. S. (2025) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2025.100303 · Cited by 4
LSD acutely impairs fear recognition and enhances emotional empathy and sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(16)31139-7 · Cited by 4
Practices in Religious Naturalism
Steinhart, E. C. (2018) · Routledge eBooks · doi:10.4324/9781315228907-30 · Cited by 4
Ramadam Fasting and Neurologic Disorders
El‐Mitwalli, A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.013 · Cited by 4
Pennycook, G., Tranel, D., Warner, K., & Asp, E. W. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.012 · Cited by 4
Microdosing Psychedelics as a Promising New Pharmacotherapeutic
Kuypers, K. P. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_18 · Cited by 4
Lutkajtis, A. (2022) · International Journal for the Study of New Religions · doi:10.1558/ijsnr.20152 · Cited by 4
Plant and Fungal Hallucinogens as Toxic and Therapeutic Agents
Carlini, E. A., & Maia, L. O. (2019) · Toxinology · doi:10.1007/978-94-007-6728-7_6-2 · Cited by 4
Unraveling the Mysteries of Mental Illness With Psilocybin
Sottile, R., Singh, H., Weisman, A., & Vida, T. (2022) · Cureus · doi:10.7759/cureus.25414 · Cited by 4
Shults, F. L. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2078591 · Cited by 4
Psychedelics for Alzheimer's Disease Palliative Care
McManus, K. R., Patrick, R. E., Striepe, M. I., Drury, M. J., Ozonsi, R., Forester, B. P., & Weinberg, M. S. (2022) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2022.06.001 · Cited by 4
Savoldi, R., Roazzi, A., Escobar, J. A. C., Nour, M. M., & Carhart-Harris, R. L. (2023) · International Journal of Latin American Religions · doi:10.1007/s41603-023-00203-y · Cited by 4
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5048-9 · Cited by 4
Addiction to Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”
Farré, M., Galindo, L., & Torrens, M. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_27 · Cited by 4
An Evolutionary Perspective on the Use of Hallucinogens
Júnior, W. S. F., Cruz, M. P., Vieira, F. J., & Albuquerque, U. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-19917-7_14 · Cited by 4
Serotonin and serotonin receptors in hallucinogen action
Halberstadt, A. L., & Nichols, D. E. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00043-8 · Cited by 4
Thomas, K. L. H., Jesse, R., Mehtani, N. J., Mitchell, J., & Anderson, B. T. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2201244 · Cited by 4
Self-citationA dual-receptor model of serotonergic psychedelicsPreprint
Juliani, A., Chelu, V., Graesser, L., & Safron, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.12.589282 · Cited by 4
Consciousness as a domain of extraterritoriality
Falcon, J. (2021) · Culture, theory and critique/Culture, theory & critique · doi:10.1080/14735784.2021.1908904 · Cited by 3
Development of the Japanese version of the Challenging Experience Questionnaire
Tani, H., Yonezawa, K., Kusudo, K., Barrett, F. S., Nakajima, S., & Uchida, H. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12456 · Cited by 3
A systematic review of psychedelic use and its relationship with meaning and purpose in life
Rupiński, P., Drabek, W., & Holas, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00442 · Cited by 3
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes
Kishon, R., & Cycowicz, Y. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1637162 · Cited by 3
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 3
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
Dallery, J., Miller, J. L., Boissoneault, J., Harvey, L., Ives, L., Knerr, A. W., Blaes, S., Ransom, M. N., Munson, M. S., Gilligan, J. P., et al. (2026) · Journal of Eating Disorders · doi:10.1186/s40337-025-01508-3 · Cited by 3
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
MacLeod, A., Clarke, V., & Warner, C. (2025) · The Arts in Psychotherapy · doi:10.1016/j.aip.2025.102284 · Cited by 3
Considerations on the Construction, Timing, and Consequences of the Psychedelic Renaissance
Dollar, C. B. (2025) · Contemporary Drug Problems · doi:10.1177/00914509251344637 · Cited by 3
Psychedelic‐Induced Experiences
Fadiman, J., & Kornfeld, A. (2013) · Wiley eBooks · doi:10.1002/9781118591277.ch19 · Cited by 3
Psychedelic Experience as a Heuristic Tool for Exploring the Mind and the Brain
Alyushin, A. (2011) · NeuroQuantology · doi:10.14704/nq.2011.9.3.419 · Cited by 3
Religion and Frontotemporal Dementia
Block, N., & Miller, B. L. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.016 · Cited by 3
Swank, M. (2020) · International Journal of Jungian Studies · doi:10.1163/19409060-bja10006 · Cited by 3
Siegel, V., & Emmert‐Aronson, B. O. (2021) · F1000Research · doi:10.12688/f1000research.53496.1 · Cited by 3
Vargas-Pérez, H., Minauro‐Sanmiguel, F., Ting‐A‐Kee, R. A., Grieder, T. E., Méndez‐Díaz, M., Prospero-Garcia, O. E., & van der Kooy, D. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137597 · Cited by 3
Psychedelika in der Psychiatrie
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2233-4301 · Cited by 3
Emmerich, N. (2024) · Neuroethics · doi:10.1007/s12152-024-09571-4 · Cited by 3
Psychedelics and moral psychology: the case of forgiveness
Chopra, S., & Letheby, C. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0010 · Cited by 3
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 3
Hendricks, P. S., & Grob, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6_14 · Cited by 3
Eastern Spirituality, Mind–Body Practices and Neuro-Rehabilitation
Yeates, G. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.018 · Cited by 3
Hallucinogen Use in College Students: Current Trends and Consequences of Use
Jia, L. S., & Gold, J. A. (2020) · Current Psychopharmacologye · doi:10.2174/2211556009666200311140404 · Cited by 3
Chan, R. H. A., & Mendelson, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00017-4 · Cited by 3
Earleywine, M., Low, F., & Leo, J. A. D. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00187 · Cited by 3
Carrigan, K., FRANÇOIS, M., Dubus, Z., & Fauvel, B. (2022) · Revue Education Santé Sociétés · doi:10.17184/eac.6033 · Cited by 3
Can self-transcendent positive emotions facilitate bonds with nature?Preprint
Moreton, S. G. (2018) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/deq8z · Cited by 3
Update of the Altered States Database (ASDB): 2022-12-31Preprint
Peters, M., Prugger, J., Dimkov, P. R., & Schmidt, T. T. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/wdfhg · Cited by 3
González-Rodriguez, D., & Perez-Carmona, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9rnj8 · Cited by 3
Petrovitch, D., Victor, S. E., Schmidt, A. T., Schmitz, J. M., Meyer, T. D., Stotts, A. L., & Littlefield, A. K. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00371-y · Cited by 3
Social Worker Attitudes towards Psychedelics
Nowakowski-Sims, E., & Holzworth, J. (2025) · Clinical Social Work Journal · doi:10.1007/s10615-025-00988-9 · Cited by 2
A scoping review of the effects of serotonergic psychedelics on attitudes towards death
Barr, N. N. T., Giese, K. J., & Moreton, S. G. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06787-x · Cited by 2
Bhatt, K. V., Compton, J. N., Ellerman-Tayag, E., Mishra, J., Perivoliotis, D., Pittman, J. O. E., Ramanathan, D., & Bismark, A. W. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0040 · Cited by 2
Andión, Ó., Bouso, J. C., Sarris, J. J., Tófoli, L. F., Opaleye, E. S., & Perkins, D. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000097 · Cited by 2
Beaussant, Y., Oglesby, C., Roddy, K., Sanders, J. J., & Agrawal, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00460 · Cited by 2
Mystical experience in the Bayesian brain
Villiger, D. (2025) · Phenomenology and the Cognitive Sciences · doi:10.1007/s11097-025-10107-1 · Cited by 2
Hosford, S., & Austin-Robillard, H. (2025) · Contemporary Family Therapy · doi:10.1007/s10591-025-09766-8 · Cited by 2
Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy
Lappan, S. N., & Davis, S. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251404021 · Cited by 2
Toward Greater Diversity in Psychedelic Science
Hughes, M. (2026) · Psychiatric Services · doi:10.1176/appi.ps.20250169 · Cited by 2
Lewis, B. R., Reid, M. C., Novick, A. M., Byrne, K., Niciu, M. J., Fonzo, G. A., Meyer, T. D., Feifel, D., El‐Mallakh, R. S., Soares, J., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251413490 · Cited by 2
Electrophysiological effects of psilocybin co-administered with midazolam
Sutherland, M. H., Nicholas, C. R. N., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Sauder, C. J., Riedner, B. A., Smith, R. F., Hutson, P. R., Raison, C. L., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03894-x · Cited by 2
Bendz, J., Schäfer, L., Sjöström, D., Sikström, S., & Kajonius, P. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644856 · Cited by 2
Low, Z. X. B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111717 · Cited by 2
Chwyl, C., Bazinet, A. D., Wilson‐Poe, A. R., Hoffman, K., Pertl, K., Wolf, R. C., Korthuis, P. T., & Luoma, J. B. (2026) · Neuroethics · doi:10.1007/s12152-026-09645-5 · Cited by 2
Low, F., & Earleywine, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2673844 · Cited by 2
Psilocybin modulates social behaviour in male and female mice in a time-dependent manner
Shadani, S., McCoy, K., Ong, L., Greaves, E., Conn, K., Andrews, Z. B., & Foldi, C. J. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02450-x · Cited by 2
Boehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 2
Bhagavan, C., Carter, O. L., Nielsen, G., Berlowitz, D. J., Issak, S., Braat, S., Zaloumis, S. G., Attard, Z., Oliver, G., Mayne, D., et al. (2026) · CNS Drugs · doi:10.1007/s40263-026-01326-4 · Cited by 2
Philosophical Hazards in the Neuroscientific Study of Religion
Haan, D. D. D. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.007 · Cited by 2
Autism and the Panoply of Religious Belief, Disbelief and Experience
Clark, K. J., & Visuri, I. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165.014 · Cited by 2
Snook, C. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_48-1 · Cited by 2
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
